九洲药业(603456) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was CNY 1,200,981,402.86, a decrease of 9.15% compared to CNY 1,321,966,893.34 in the same period last year[1]. - Net profit attributable to shareholders for Q3 2024 was CNY 155,888,065.39, down 54.80% from CNY 345,043,114.27 year-on-year[1]. - The basic earnings per share for Q3 2024 was CNY 0.17, a decline of 58.54% compared to CNY 0.41 in the same period last year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 3,965,261,223.17, a decrease of 13.4% compared to CNY 4,576,609,415.43 in the same period of 2023[16]. - Net profit for the first three quarters of 2024 was CNY 632,852,491.81, a decline of 34.4% from CNY 964,411,448.85 in the same period of 2023[17]. - The total comprehensive income for the first three quarters of 2024 was CNY 628.98 million, compared to CNY 970.20 million in the same period of 2023, a decrease of approximately 35.2%[18]. - The company's total comprehensive income attributable to shareholders was CNY 627.01 million for the first three quarters of 2024, down from CNY 972.55 million in the same period of 2023, a decrease of about 35.5%[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 11,008,581,078.46, an increase of 1.44% from CNY 10,851,987,356.69 at the end of the previous year[4]. - The company's total liabilities amounted to CNY 2,385,504,566.85 in Q3 2024, an increase from CNY 2,318,916,463.48 in Q3 2023, reflecting a rise of 2.9%[14]. - The equity attributable to shareholders of the parent company rose to CNY 8,549,162,888.63 in Q3 2024, compared to CNY 8,461,133,056.22 in Q3 2023, an increase of 1.0%[15]. - Long-term equity investments decreased to CNY 31,475,203.17 in Q3 2024 from CNY 55,704,833.79 in Q3 2023, a decline of 43.5%[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 654,028,177.61, a decrease of 42.89% compared to CNY 1,145,267,855.24 in the same period last year[4]. - The net cash flow from operating activities for the year-to-date period decreased by 42.89%, mainly due to a reduction in received payments[8]. - Net cash flow from operating activities for the first three quarters of 2024 was CNY 3.29 billion, down from CNY 3.42 billion in 2023, indicating a decrease of approximately 3.8%[19]. - The net cash flow from investing activities was -CNY 747.14 million for the first three quarters of 2024, compared to -CNY 751.36 million in the same period of 2023, showing a slight improvement[20]. - The company reported a net cash outflow from financing activities of -CNY 477.78 million in the first three quarters of 2024, contrasting with a net inflow of CNY 2.71 billion in the same period of 2023[20]. - Cash and cash equivalents at the end of the third quarter of 2024 stood at CNY 2.50 billion, down from CNY 3.79 billion at the end of the third quarter of 2023, a decrease of approximately 34.1%[20]. Strategic Initiatives - The company plans to strengthen cooperation with key clients and expand its customer base to increase order volume[4]. - The company aims to enhance its R&D capabilities and accelerate global business expansion by establishing wholly-owned subsidiaries in Japan and Germany[4]. - The company will continue to focus on technology-driven growth and the rapid development of emerging businesses[4]. - Research and development expenses for the first three quarters of 2024 were CNY 240,137,612.13, slightly up from CNY 239,837,436.31 in 2023, indicating a stable investment in innovation[16]. - The company completed the deregistration of its subsidiary, Zhejiang Raybow Life Science Technology Co., Ltd., on September 2, 2024[10]. - A new wholly-owned subsidiary in Singapore was established on August 15, 2023, and renamed Jiuzhou Pharmaceutical (Singapore) PTE. LTD. on September 12, 2024[11]. - The company signed a share transfer agreement with Fangda Pharmaceutical Technology (Shanghai) Co., Ltd. for a 25% stake in Fangda Suzhou, with a transaction price of RMB 19.6 million[12]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 48,424[9]. - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. held 31.52% of the shares, making it the largest shareholder[9].